How are you capping drug prices in absence of norms? HC to NPPA

How are you capping drug prices in absence of norms? HC to NPPA

FPJ BureauUpdated: Saturday, June 01, 2019, 08:04 AM IST
article-image

The court asked NPPA to file an affidavit clarifying its stance on whether it has powers to fix prices of non-essential drugs

New Delhi : The Delhi High Court on Tuesday asked the National Pharmaceutical Pricing Authority (NPPA) to show the manner in which it is exercising its power to cap prices of non-scheduled drugs in view of the recent withdrawal of the guidelines issued for the purpose, reports PTI.

“It’s not that you do not have the power for carrying out the exercise, it’s the manner in which you exercise it that is being questioned,” the bench said after the counsel for the NPPA contended that withdrawal of the guidelines has not taken away the authority’s power to fix prices.

“File an affidavit indicating framework within which prices for non-scheduled drugs are now sought to be sustained in the absence of the guidelines,” it said.

The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers had on September 19 ordered the NPPA to withdraw a guideline under the Drug (Prices Control) Order (DPCO) of 2013 that gave the pricing authority powers to cap prices of non-scheduled drugs.

The NPPA had on the basis of the May 29 guideline issued a notification on July 10 capping prices of 108 anti-diabetic and cardiovascular drugs.

Senior advocate Kapil Sibal, appearing for the Organisation of Pharma Producers of India (OPPI), said since the guidelines for the price fixation of drugs has been withdrawn, it would also affect the operation of the July 10 notification.

The OPPI has moved the court challenging the notification and seeking an order preventing the government from taking any further steps in pursuance of the same.

RECENT STORIES

Kolkata Real Estate Developers Urge Union Budget To Revise Affordable Housing Definition, & Boost...
Kolkata Real Estate Developers Urge Union Budget To Revise Affordable Housing Definition, & Boost...
Executive Centre India Gets SEBI Nod For ₹2,600 Crore IPO, Entirely Fresh Issue To Fund...
Executive Centre India Gets SEBI Nod For ₹2,600 Crore IPO, Entirely Fresh Issue To Fund...
Groww Q3 Revenue Rises To ₹1,216 Crore, Q3 Net Profit Dips 28%, Contrasting With Q1 & Q2 Growth...
Groww Q3 Revenue Rises To ₹1,216 Crore, Q3 Net Profit Dips 28%, Contrasting With Q1 & Q2 Growth...
India’s Real Estate Sector Hits Record $14.3 Billion Capital Inflows In 2025, Up 25% YoY
India’s Real Estate Sector Hits Record $14.3 Billion Capital Inflows In 2025, Up 25% YoY
WPI Inflation Turns Positive At 0.83% After Two Months Of Deflation, Driven By Food & Manufactured...
WPI Inflation Turns Positive At 0.83% After Two Months Of Deflation, Driven By Food & Manufactured...